Medications for the treatment of obesity

C Carette; C Rives-Lange; S Czernichow

doi:10.1016/j.jviscsurg.2022.12.002

Medications for the treatment of obesity

J Visc Surg. 2023 Apr;160(2S):S12-S14. doi: 10.1016/j.jviscsurg.2022.12.002. Epub 2023 Jan 30.

Authors

C Carette¹, C Rives-Lange¹, S Czernichow²

Affiliations

¹ Paris Cité University, Nutrition Department, Specialized Obesity Center, Georges Pompidou European Hospital, AP-HP, 20, rue Leblanc, Paris, France.
² Paris Cité University, Nutrition Department, Specialized Obesity Center, Georges Pompidou European Hospital, AP-HP, 20, rue Leblanc, Paris, France. Electronic address: sebastien.czernichow@aphp.fr.

PMID: 36725455
DOI: 10.1016/j.jviscsurg.2022.12.002

Abstract

After several years with no real therapeutic alternatives, the management of obesity is entering a new era with the development of new surgical and endoscopic bariatric techniques, digital therapeutics and the arrival of new classes of drugs. New medication treatments aim to reduce food intake, targeting the hypothalamic regulation of food intake and satiety. The mechanism of their action remains poorly understood but, combines weight reduction and amelioration of cardiometabolic risk factors with a favorable benefit-risk balance and known side effects, mainly digestive. The future will tell us how these drugs will find their place in the management of this chronic disease that is obesity.

Keywords: GLP1 receptor agonists; Glucagon intestinal peptide (GIP); Hypothalamus; Leptin-melanocortin Leptin; Suspensive pharmacotherapy.

MeSH terms

Humans
Hypothalamus / metabolism
Leptin* / metabolism
Leptin* / pharmacology
Obesity* / drug therapy

Substances

Leptin